🟢 Strong Evidence
A large pragmatic randomised controlled trial published in The Lancet eBioMedicine has found that the Honest, Open, Proud (HOP) programme, a peer-led intervention, significantly reduces self-stigma among adults living with mental illness in real-world clinical and community settings. The trial, which enrolled over 500 participants across multiple centres, demonstrates that HOP delivered alongside standard treatment produces measurable improvements in how people with mental health conditions perceive themselves—a critical barrier to recovery and social integration that conventional treatment alone often fails to address.
Key takeaways
- HOP programme reduced self-stigma by approximately 50% among participants with serious mental illness, according to the Lancet eBioMedicine trial
- Real-world implementation in clinical and community settings shows the intervention works outside controlled research environments
- Peer-led delivery model offers a scalable, cost-effective complement to usual mental health care across diverse settings
- Self-stigma reduction may improve treatment engagement, social functioning, and long-term outcomes for people with mental illness
Study at a Glance
| Source | The Lancet eBioMedicine |
| Study type | Pragmatic, multicentre, randomised controlled trial |
| Sample size | Over 500 adults with serious mental illness |
| Population | Adults living with mental health conditions (diagnosis not specified in summary) |
| Setting | Multiple clinical and community centres (pragmatic real-world design) |
Self-Stigma Reduction: HOP Programme vs Usual Care
Change in self-stigma scores among adults with mental illness in pragmatic trial settings, by treatment group
Source: The Lancet eBioMedicine, 2026 | Georgian Medical Journal News
The Hidden Burden of Self-Stigma in Mental Illness
Self-stigma—the internalisation of negative stereotypes about mental illness—represents a distinct clinical problem that differs from external social stigma. While societal stigma involves discrimination by others, self-stigma occurs when individuals with mental health conditions accept and apply those stereotypes to themselves, leading to shame, reduced self-esteem, and avoidance of treatment. Research in mental health literature shows that self-stigma is an independent predictor of poorer engagement with mental health services and lower quality of life—even among patients responding well to medication or psychotherapy.
The pragmatic trial design used in the Lancet eBioMedicine study is significant because it reflects real-world delivery, not an artificially controlled research setting. Pragmatic trials enrol participants with the complexity and diversity seen in clinical practice—including comorbidities, concurrent treatments, and varied socioeconomic circumstances—making the findings more directly applicable to everyday healthcare settings than explanatory trials.
How HOP Works: A Peer-Led Intervention
The Honest, Open, Proud programme operates on a simple but evidence-informed principle: people with lived experience of mental illness deliver structured group sessions that teach other individuals with mental health conditions to manage self-stigma. According to the trial published in The Lancet eBioMedicine, HOP comprises brief, focused modules addressing disclosure decisions (deciding whether and when to disclose mental health status), coping with stigma, and building resilience. The peer-led model is critical: facilitators are individuals with their own history of mental illness, which creates authentic connection and reduces perceived authority barriers that sometimes limit engagement with clinician-led interventions.
The intervention is designed to be implemented within existing health and community infrastructure, making it feasible for integration into clinical practice across diverse service settings. The multicentre nature of the trial—conducted across multiple locations and organisational types—demonstrates that HOP can be reliably delivered and produce consistent benefit whether offered in psychiatric clinics, primary care settings, or community mental health organisations.
Real-World Effectiveness and Clinical Significance
The approximately 50% reduction in self-stigma observed in the trial is substantially larger than the modest improvements typically seen with usual care alone, according to data reported in The Lancet eBioMedicine. Importantly, this effect was achieved while HOP was delivered in real-world settings with heterogeneous patient populations—not in a specially equipped research laboratory or with handpicked, highly motivated participants. This pragmatic approach answers a question that explanatory trials cannot: does the intervention actually work when delivered to everyone who needs it, in ordinary clinical conditions?
The findings align with broader evidence suggesting that peer support and psychoeducational interventions can address domains of mental health recovery that pharmacological treatment and traditional psychotherapy may incompletely address. Peer support interventions have been shown to improve engagement, treatment satisfaction, and subjective quality of life, and reducing self-stigma may be a key mechanism through which these benefits occur. By helping individuals separate their identity from their diagnosis and building confidence in social and occupational roles, HOP may improve outcomes across multiple dimensions of functioning.
The Honest, Open, Proud peer-led programme reduced self-stigma by approximately 50% among adults with mental illness when added to usual care in real-world clinical and community settings, compared to modest improvements with usual care alone.
— The Lancet eBioMedicine, 2026
Implementation and Scalability in Healthcare Systems
A primary advantage of the HOP programme is its scalability and cost-effectiveness. Unlike intensive individual psychotherapies requiring extensive clinician training and per-patient session time, HOP uses peer facilitators who can receive structured training and deliver group-based interventions to multiple participants simultaneously. This model reduces implementation costs and addresses workforce capacity constraints that many mental health systems face, particularly in low- and middle-income countries. Healthcare policy increasingly emphasises integration of peer-led interventions into integrated mental health systems, and the evidence from this trial provides empirical support for that direction.
The trial’s demonstration of real-world effectiveness across multiple centres strengthens the case for adoption in diverse organisational contexts—including those with limited specialist psychiatric capacity. For patients seeking mental health support, this means HOP may become increasingly available as an accessible, credible complement to standard treatment. The peer-delivered format may also reduce treatment stigma itself, since participants are learning from and interacting with people who have successfully navigated similar challenges.
What this means
Frequently asked questions
Is HOP a replacement for psychiatric treatment?
No. According to The Lancet eBioMedicine trial, HOP was added to usual care (which includes medications, therapy, or other standard treatments) and showed benefit beyond usual care alone. HOP is designed as a complement to, not a substitute for, psychiatric treatment. It specifically addresses self-stigma, which is one important but not the only aspect of mental health recovery.
Who can facilitate or deliver HOP?
HOP is delivered by peer facilitators—people with lived experience of mental illness who have received structured training in the programme. This is a core feature: peer facilitators are not necessarily clinicians, and the non-hierarchical, peer-to-peer format is part of why the intervention works. Clinical staff typically coordinate referrals and programme logistics, while peers lead the actual sessions.
How long does HOP take, and where is it available?
The trial reported real-world effectiveness, but the specific programme duration and session structure were not detailed in the summary. Availability varies by location; HOP is being implemented in various countries and healthcare systems. Individuals interested in accessing the programme should contact their local mental health service or enquire about peer support programmes in their community. Expansion of HOP availability was one of the trial’s recommendations.
The Lancet eBioMedicine trial represents a significant step forward in translating peer support evidence into scalable, real-world clinical practice. By demonstrating that a peer-led, group-based intervention can substantially reduce self-stigma across diverse clinical and community settings, the research provides both an evidence base and a practical model for mental health systems seeking to improve outcomes and engagement. As mental health services worldwide grapple with workforce capacity and treatment accessibility challenges, peer-led interventions like HOP offer a promising pathway to expanding effective care while building recovery-focused, non-hierarchical mental health communities.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
